WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Research

Introduction: Principle and Scientific Rationale

WY-14643 (Pirinixic Acid) is a benchmark research tool for dissecting the PPAR signaling pathway in metabolic and inflammatory contexts. This selective PPARα agonist (IC₅₀=10.11 μM for human PPARα) is widely utilized for its potent and consistent activation of PPARα, a nuclear receptor pivotal in lipid metabolism regulation, fatty acid oxidation, and inflammatory modulation. Structurally, aliphatic α-substitution further enhances its dual PPARα/γ agonist activity, expanding its translational utility to studies involving both metabolic and inflammatory endpoints.

Research applications span from insulin sensitivity enhancement and anti-inflammatory agent studies in endothelial cells to advanced models of metabolic disorder research. Notably, recent work demonstrates its unique role in driving liver regeneration via the YAP-TEAD axis, highlighting its multifaceted impact on hepatocyte proliferation and tissue repair (see supporting article).

Step-by-Step Experimental Workflow: Protocol Enhancements with WY-14643 (Pirinixic Acid)

Preparation and Handling

• Compound Solubility: WY-14643 is a solid, insoluble in water, but readily dissolves in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonication). For in vitro assays, prepare concentrated DMSO stocks and dilute into serum-containing media immediately prior to use.
• Storage: Store powder at -20°C. Prepare fresh solutions for short-term use (<1 week at 4°C) to maintain activity.

Cell-Based Assays

1. Seed cells (e.g., HUVECs, hepatocytes, or relevant metabolic models) at optimal density and allow to adhere overnight.
2. Pretreat with 50–250 μM WY-14643 for 1–24 hours depending on endpoint (e.g., 250 μM for 24 h to assess VCAM-1 downregulation and monocyte adhesion reduction in endothelial inflammation models).
3. To model TNF-α mediated inflammation, stimulate with TNF-α (e.g., 10 ng/mL) after WY-14643 pretreatment. Quantify adhesion molecule expression, cytokine secretion, or monocyte adhesion using standard assays (e.g., qPCR, immunofluorescence, flow cytometry).
4. For metabolic studies, assess lipid accumulation, fatty acid oxidation, or insulin sensitivity via Oil Red O staining, radiolabeled substrate oxidation, or glucose uptake assays, respectively.

In Vivo Protocols

1. Administer WY-14643 by oral gavage (e.g., 3 mg/kg/day for 2 weeks in high-fat diet-fed rats) or by intraperitoneal injection (100 mg/kg/day in mice, as in the YAP-TEAD liver regeneration study).
2. Monitor metabolic parameters: plasma glucose, triglycerides, leptin, and tissue lipid content using commercial kits.
3. For liver regeneration models, perform partial hepatectomy (PHx) in Pparafl/fl and PparaΔHep mice, followed by WY-14643 treatment and serial tissue collection (2 and 5 days post-surgery). Analyze histological endpoints (H&E staining, β-catenin, and KI67 immunohistochemistry).

For detailed in vivo workflow comparisons and data-backed protocol scenarios, see the scenario-driven insights in this practical solutions article.

Advanced Applications and Comparative Advantages

Driving Liver Regeneration and Hepatomegaly: YAP-TEAD Axis

The role of WY-14643 in promoting liver regeneration is underpinned by its ability to activate PPARα-dependent signaling, which, in turn, interfaces with the YAP-TEAD transcriptional complex. In a pivotal mouse study (reference), daily intraperitoneal administration of 100 mg/kg WY-14643 robustly induced hepatomegaly and accelerated liver regeneration following PHx. This effect was abrogated in PparaΔHep and YapΔHep mice, confirming the essential role of both PPARα and YAP-TEAD in mediating these regenerative outcomes. Data-driven metrics included increased hepatocyte size, higher KI67+ cell counts (proliferation), and improved liver function markers (ALT, AST, ALB).

Metabolic Disorder Research: Insulin Sensitization and Lipid Regulation

In metabolic models, WY-14643 (Pirinixic Acid) administration (3 mg/kg/day, 2 weeks, high-fat-fed rats) led to multidimensional improvements: significant reductions in plasma glucose, triglycerides, leptin, visceral and liver fat, and muscle triglycerides, alongside a marked increase in whole-body insulin sensitivity—all without body weight gain. These effects stem from selective PPARα activation, and are further enhanced by the compound’s partial dual PPARγ agonism, broadening its relevance for complex metabolic disorder models.

Anti-Inflammatory Mechanisms in Endothelial Cells

WY-14643 demonstrates potent anti-inflammatory effects by downregulating VCAM-1 in TNF-α–stimulated human endothelial cells, reducing monocyte adhesion by over 40% in some studies. This positions WY-14643 as a leading anti-inflammatory agent in endothelial cells and a useful comparator for dissecting TNF-α mediated inflammation against other nuclear receptor agonists.

Comparative Literature Landscape

• "Reliable PPARα Agonist Solutions" complements this review by addressing reproducibility and assay optimization for cell viability and metabolic research.
• "Selective PPARα Agonist for Metabolic Disorder Research" extends the mechanistic rationale, providing practical insights into dual PPARα/γ activity and translational endpoints.
• "Driving Liver Regeneration via PPAR Signaling" offers atomic-level insights and protocol comparatives for inflammation and metabolic disorder workflows.

Troubleshooting and Optimization Tips

• Compound Solubility: For high-concentration in vivo dosing, use ethanol with sonication or DMSO as a co-solvent, then dilute into corn oil or aqueous vehicles immediately prior to administration. Avoid repeated freeze-thaw cycles of stock solutions.
• Cytotoxicity Control: In cell assays, titrate WY-14643 concentrations carefully (typically 1–250 μM), and always include DMSO-only controls to distinguish compound effects from solvent toxicity.
• Batch Consistency: Source from a reputable supplier. APExBIO’s WY-14643 (SKU A4305) is widely cited for batch-to-batch reliability, critical for reproducible metabolic and inflammatory studies.
• In Vivo Formulation: For chronic dosing (e.g., 2–4 week studies), prepare fresh WY-14643 solutions daily to prevent degradation. Use ultrasonic assistance when dissolving in ethanol or corn oil.
• Endpoint Validation: Confirm PPARα activation by measuring canonical target gene induction (e.g., ACOX1, CPT1A) via qPCR, and validate anti-inflammatory endpoints using both gene expression and functional assays (e.g., monocyte adhesion).
• Model-Specific Dosing: Tailor dosing regimens to the species, disease model, and desired outcome (e.g., 3 mg/kg/day for metabolic studies in rats, 100 mg/kg/day for liver regeneration in mice). Consult recent workflows (see Q&A on protocol design).
• Histological Analysis: For liver regeneration studies, embed samples promptly in paraffin and use validated antibodies (e.g., β-catenin, KI67) for immunohistochemistry. Employ automated image analysis (ImageJ) for quantitative morphometry.

Future Outlook: Expanding WY-14643 Utility in Metabolic and Regenerative Research

As the field advances, WY-14643 (Pirinixic Acid) is poised to remain a gold-standard PPARα agonist for metabolic research, with expanding roles in regenerative medicine and cardiometabolic disease modeling. The convergence of PPAR signaling with YAP-TEAD and other nuclear receptor pathways opens new avenues for dissecting tissue-specific regeneration, fibrosis, and inflammation. Emerging use-cases include combination studies with verteporfin (YAP-TEAD inhibitor) or AAV-YAP-shRNA for pathway dissection, as demonstrated in recent mouse models (reference backbone).

For researchers seeking robust, validated workflows and reproducible results, WY-14643 (Pirinixic Acid) from APExBIO remains a trusted choice. Ongoing protocol refinement and integration with omics technologies will further enhance its impact on metabolic disorder and liver regeneration studies.